Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Novatis

- PMLiVE

Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

Novartis day

Cosentyx, Entresto drive topline growth for Novartis in Q4

Overall net income fell for the full year compared to 2018

- PMLiVE

Novartis picks up inclisiran after completion of MedCo acquisition

If approved could become blockbuster cholesterol treatment

- PMLiVE

Novartis grows in Q3 thanks to stellar performance of key drugs

Cosentyx, Entresto and Zolgensma topped drive sales growth

Novartis day

Blow for Entresto in latest heart failure trial

Aim of being first in HFpEF in serious doubt

- PMLiVE

Novartis aims for 10 blockbuster launches by 2020

Includes new gene therapy Zolgensma

- PMLiVE

Afinitor and Uptravi gain funding from NHS England

Rare disease treatments navigate tricky market access route

- PMLiVE

Novartis’ heart failure drug Entresto proves superior to enalapril

Results could see the drug strengthen its position in the market

- PMLiVE

Real-world data finds patients feel better on Entresto, says Novartis

Patients on Entresto reported an “early, statistically significant improvement in health status”

- PMLiVE

Novartis’ orphan drug Tasigna wins EU expanded indication

The CML medication can now treat paediatric patients

- PMLiVE

CV data sets up Novartis’ Ilaris for blockbuster sales

Drug shown to reduce major adverse cardiovascular events

- PMLiVE

New drugs can’t keep Novartis sales on the up

Total group sales down 1% despite Cosentyx profit

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links